1. Home
  2. BLFY vs VYGR Comparison

BLFY vs VYGR Comparison

Compare BLFY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLFY
  • VYGR
  • Stock Information
  • Founded
  • BLFY 1939
  • VYGR 2013
  • Country
  • BLFY United States
  • VYGR United States
  • Employees
  • BLFY N/A
  • VYGR N/A
  • Industry
  • BLFY Commercial Banks
  • VYGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLFY Finance
  • VYGR Health Care
  • Exchange
  • BLFY Nasdaq
  • VYGR Nasdaq
  • Market Cap
  • BLFY 204.2M
  • VYGR 172.6M
  • IPO Year
  • BLFY N/A
  • VYGR 2015
  • Fundamental
  • Price
  • BLFY $9.38
  • VYGR $3.57
  • Analyst Decision
  • BLFY Hold
  • VYGR Strong Buy
  • Analyst Count
  • BLFY 2
  • VYGR 8
  • Target Price
  • BLFY $11.00
  • VYGR $14.33
  • AVG Volume (30 Days)
  • BLFY 60.2K
  • VYGR 680.6K
  • Earning Date
  • BLFY 07-30-2025
  • VYGR 08-05-2025
  • Dividend Yield
  • BLFY N/A
  • VYGR N/A
  • EPS Growth
  • BLFY N/A
  • VYGR N/A
  • EPS
  • BLFY N/A
  • VYGR N/A
  • Revenue
  • BLFY $41,228,000.00
  • VYGR $66,958,000.00
  • Revenue This Year
  • BLFY $20.14
  • VYGR N/A
  • Revenue Next Year
  • BLFY $20.20
  • VYGR $78.88
  • P/E Ratio
  • BLFY N/A
  • VYGR N/A
  • Revenue Growth
  • BLFY N/A
  • VYGR N/A
  • 52 Week Low
  • BLFY $8.34
  • VYGR $2.65
  • 52 Week High
  • BLFY $11.48
  • VYGR $9.55
  • Technical
  • Relative Strength Index (RSI)
  • BLFY 49.32
  • VYGR 63.79
  • Support Level
  • BLFY $9.49
  • VYGR $3.00
  • Resistance Level
  • BLFY $10.00
  • VYGR $3.43
  • Average True Range (ATR)
  • BLFY 0.30
  • VYGR 0.18
  • MACD
  • BLFY 0.01
  • VYGR 0.06
  • Stochastic Oscillator
  • BLFY 47.01
  • VYGR 97.50

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: